Goldman Sachs likely to invest Rs 2,700 crore in PharmEasy parent
Written by: Diksha Kalra
Published: May 18, 2022
Updated: Jul 26, 2024
1 min read
Goldman Sachs is in advanced talks to invest about $350 million (Rs. 2,700 crores) in API Holdings Ltd., the parent of online pharmacy PharmEasy, in a structured debt transaction.
The debt will carry an interest rate of 14-15% and also have a pre-agreed equity upside, or a premium to the rate based on potential increase in the company's valuation. The money will predominantly be used to refinance the debt the company had taken to fund its acquisition of diagnostic chain Thyrocare last year.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Planify Enterprises Private Limited
Planify Capital Limited
Licensed By
Mutual Fund License No.:
ARN-164419
IRDA Code (1):
ABLIC1003123454
IRDA Code (2):
ABLIC1003131639
Startup India Certificate No.:
DIPP93786
Other Websites
Address
MiQB, Plot 23, Sector 18, Maruti Industrial Development Area, Opposite VLCC corporate office, Gurugram, Haryana 122015
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India
